Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
NCT00828932 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2019-09-12
Summary
The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.
Conditions
- Hepatic Impairment
Interventions
- DRUG
-
Lorcaserin
Sponsors & Collaborators
-
Eisai Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-08-31
- Primary Completion
- 2008-12-31
- Completion
- 2008-12-31
Countries
- United States
Study Locations
More Related Trials
-
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
NCT04252495 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers
NCT01529294 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
NCT06928779 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
NCT04887064 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
NCT05935033 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011
NCT02388620 ·Status: COMPLETED ·Phase: PHASE1
-
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
NCT04604496 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
NCT01197911 ·Status: COMPLETED ·Phase: PHASE1
-
Hepatic Impairment Trial of Obeticholic Acid
NCT01904539 ·Status: COMPLETED ·Phase: PHASE1
-
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
NCT02421042 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone
NCT06388616 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
NCT00432627 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
NCT01516047 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.
NCT03290443 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
NCT06952634 ·Status: COMPLETED ·Phase: PHASE1
-
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
NCT04193436 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
NCT02857868 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
NCT01950481 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics
NCT00692341 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
NCT02387814 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function
NCT04226833 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
NCT03515980 ·Status: COMPLETED ·Phase: PHASE1